The Cancer Targeted Therapy Market is witnessing rapid expansion due to the increasing adoption of precision medicine, rising cancer incidence globally, and continuous advancements in targeted treatment approaches. The cancer targeted therapy market size is expected to reach US$ 235,680.29 million by 2031 from US$ 95,120.20 million in 2024. The market is estimated to record a CAGR of 14.0% from 2025 to 2031, highlighting strong growth potential fueled by innovation in oncology therapeutics.
Cancer targeted therapies are designed to specifically identify and attack cancer cells by interfering with molecular targets involved in tumor growth and progression. These therapies offer significant advantages over traditional chemotherapy, including improved treatment precision, reduced side effects, and enhanced patient outcomes. Increasing focus on personalized medicine and biomarker-based therapies is further accelerating the growth of the Cancer Targeted Therapy Market.
Request Sample Pages of this Research Study @ https://www.businessmarketinsights.com/sample/BMIPUB00031706
Market Segmentation Analysis
By Therapy Type
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Cancer Vaccines
- Gene Therapy
- Others
By Indication
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Colorectum Cancer
- Prostate Cancer
- Stomach Cancer
- Cervical Cancer
- Liver and Intrahepatic Bile Duct Cancer
- Thyroid Cancer
- Others
By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
Regional Insights
North America dominates the Cancer Targeted Therapy Market due to advanced healthcare infrastructure, high adoption of innovative treatment technologies, and strong presence of leading pharmaceutical and medical device companies. Europe also holds a substantial share, supported by increasing investment in cancer research and favorable healthcare policies.
Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by rising cancer incidence, improving healthcare infrastructure, and increasing access to advanced treatment options. Countries such as India, China, and Japan are investing significantly in oncology research and healthcare modernization.
Competitive Landscape and Key Company Profiles
- Astellas Pharma Inc
- Eli Lilly and Co
- Novartis AG
- Merck KGaA
- Johnson & Johnson
- AstraZeneca
- Pfizer Inc
- Bristol Myers Squibb
- F. Hoffmann-La Roche Ltd
- AbbVie
Cancer Targeted Therapy Market Drivers and Opportunities:
Advancements in Genomic Profiling and Biomarker Discovery Driving Cancer Targeted Therapy Market
Emergence of genomic profiling and biomarker discovery are powerful agents of growth in the cancer targeted therapy marketplace, reshaping how cancer is diagnosed, stratified, and treated. Strides are being made to move away from the one-size-fits-all approach to cancer therapy to precision medicine approaches with detailed molecular information about the molecular drivers of individual tumors. Next-generation sequencing (NGS), whole exome sequencing, and liquid biopsies have allowed scientists and clinicians to discover many actionable genetic mutations (e.g., EGFR, ALK, KRAS, BRAF, HER2) that serve as targets for variable levels of specificity and other available or developing therapies.
Cancer Targeted Therapy Market News and Key Development:
The cancer targeted therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the cancer targeted therapy market are:
- The FDA approved telisotuzumab vedotin (Emrelis) for adult patients with previously treated, locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) who have high c-Met protein overexpression. This antibody-drug conjugate (ADC) represents a targeted chemotherapy approach. (Source: AbbVie, Press Release, May 2025)
- Eli Lilly and Company announced that the US FDA approved an expanded indication for Verzenio (abemaciclib). High-risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade (4+ positive nodes, or 1-3 positive nodes and at least one of the following: tumors that of Grade 3). This expanded adjuvant indication removes the Ki-67 score requirement for patient selection. (Source: Eli Lilly and Company, Company Website, March 2023)
Future Outlook
The Cancer Targeted Therapy Market is expected to experience robust growth in the coming years, driven by increasing cancer prevalence, advancements in precision medicine, and growing adoption of innovative treatment approaches. The integration of advanced technologies such as artificial intelligence, robotics, and molecular diagnostics is further enhancing the effectiveness of targeted therapies and surgical procedures.
As healthcare systems worldwide continue to prioritize patient-centric care and improved clinical outcomes, the Cancer Targeted Therapy Market will offer significant opportunities for manufacturers, healthcare providers, and investors. Continuous innovation and expanding access to advanced therapies will remain key drivers of long-term market growth.
Buy Latest Report @ https://www.businessmarketinsights.com/buy/BMIPUB00031706
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.
Contact us:
- If you have any questions about this report or would like further information, please contact us:
- Contact person: Ankit Mathur
- Email: sales@businessmarketinsights.com
- Phone: +16467917070
